Asundexian lowered ischemic stroke without more major bleeding across low, intermediate, and high Framingham risk groups (all P interaction > .25).
News|Articles|December 19, 2025
2025 Brings Real-World Use of Clinical Biomarkers in Updated Multiple Sclerosis Diagnostic Criteria
Author(s)Isabella Ciccone, MPH
Fact checked by: Patrick Campbell
Discover how updated diagnostic criteria for multiple sclerosis enhance accuracy and confidence in clinical practice, utilizing advanced imaging and biomarkers.
Advertisement
Advertisement
The latest diagnostic criteria for multiple sclerosis (MS) were initially presented at the
Related to this article
End-of-study B-Well data show 91% of patients with chronic hepatitis B who achieved functional cure with bepirovirsen maintained it through Week 96.
With LDL-C target-guided titration, starting statin plus ezetimibe vs a statin alone yielded similar 3-year events in ASCVD.
Stopping statins was noninferior at 2 years in adults 70 and older without CVD, but events were higher over full follow-up (12.7% vs 9.2%).
Post hoc phase 2 data show survodutide improved MASH and fibrosis endpoints across all weight loss categories, including patients losing less than 5%.
Adding spironolactone lowered 3-month home SBP by 7.7 mm Hg vs standard care in 160 stroke survivors with uncontrolled hypertension.
A systolic target below 120 mm Hg lowered major cardiovascular events vs below 140 mm Hg in 4368 patients with prior ischemic stroke or TIA.
Chronic hypertension in pregnancy was tied to 30% higher odds of critical congenital heart disease in a study of 44 million US births.
Advertisement
Advertisement